AREAS OF RESEARCH

Tuberculosis

Tuberculosis is one of the deadliest infectious diseases and India has the highest number of patients suffering from tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB). Patients have to undergo a minimum of 6 months of treatment and serious side effects using existing drug therapy. There is an urgent need for new anti-TB drugs which reduce treatment duration, work on drug resistant tuberculosis and have lesser side effects. 

 

FNDR’s TB therapeutics program is focused on discovering small molecules that have novel chemical scaffolds, work on different targets and are synergistic with existing standard of care. Another focus area is compounds that are host-immunomodulators that can shorten the duration of treatment of TB. Please click here to see FNDR's current research programs on tuberculosis. 

Nontuberculous mycobacteria (NTM)

Nontuberculous mycobacteria (NTMs) are ubiquitous environmental pathogens that cause opportunistic progressive lung damage and respiratory failures in individuals with immunodeficiency or with structural lung diseases. There is an urgent need for drugs that work against drug resistance NTMs. 

FNDR’s NTM program is focused on discovering small molecules with novel chemical scaffolds that are synergistic with standard of care, work on drug resistant NTMs and biofilms. Please click here to see FNDR's current research programs on nontuberculous mycobacterial infections. 

Serious Bacterial Infections

Drug resistant bacterial infections are already a major public health concern, and the scenario is expected to worsen in the future. There is an urgent need to develop new treatments. FNDR’s serious bacterial infections program is focused on small molecule therapeutics that have novel chemical scaffolds, novel mechanism of action and that work on CDC and WHO priority pathogens. Please click here to see FNDR's current research programs on serious bacterial infections.

Serious Fungal Infections

Drug resistant fungal infections are already a major public health concern, and the scenario is expected to worsen in the future. There is an urgent need to develop new treatments. FNDR’s serious fungal infections program is focused on small molecule therapeutics that have novel chemical scaffolds, novel mechanism of action and that work on CDC and WHO priority pathogens. Please click here to see FNDR's current research programs on serious fungal infections.

Viral Infections 

FNDR’s small molecule antiviral therapeutics program is focused on the following areas  - broad spectrum antivirals that work on respiratory viruses of pandemic potential such as influenza and coronaviruses, including COVID-19 and other respiratory pathogens such as the human Respiratory Syncytial Virus (hRSV);  and vector transmitted viruses such as Dengue, Chikungunya, Zika, West Nile and Japanese encephalitis Virus (JEV), where antivirals are not available. Please click here to see FNDR's current research programs on viral infections.

Parasitic Infections

Malaria, a mosquito borne infectious disease caused by Plasmodium parasites, is a life-threatening disease. According to WHO, approximately half of the world’s population was at risk of malaria in 2020. There is an urgent need for new medicines that can treat malaria with one dose or those that work against drug resistant malaria. 

 

Leishmaniasis is a parasitic Neglected Tropical Disease (NTD) that is spread through infected sandflies and is predominant in the tropical regions. There is an urgent need to develop oral therapeutic agents that work against leishmaniasis. Please click here to see FNDR's current research programs on parasitic infections.